casirivimabimdevimab sold brand name among combination medicine used treatment prevention consists two human monoclonal antibodies casirivimab imdevimab must mixed together administered infusion subcutaneous combination two antibodies intended prevent mutational also available coformulated developed american biotechnology company regeneron common side effects include allergic reactions include infusion related reactions injection site brief pain weakness combination approved brand name ronapreve medical use japan united kingdom european union january us food drug administration fda revised authorizations two monoclonal antibody treatments bamlanivimabetesevimab administered together casirivimabimdevimab limit use recipients likely infected exposed variant susceptible treatments data show treatments highly unlikely active omicron european union combination indicated treatment people aged twelve years age older weighing least kilograms lb require supplemental oxygen high increased risk progressing severe prevention people aged twelve years age older weighing least kilograms manufactured regenerons manufacturing facility rensselaer new september free manufacturing capacity regeneron began shift production existing products rensselaer irish city regeneron deal place roche manufacture market outside united october regeneron pharmaceuticals announced thenus president donald trump received single gram dose testing positive drug provided company response compassionate use temporary authorization use request presidents august texas governor greg abbott received testing positive january united states agreed purchase million doses drug billion per september another million doses purchased price totaling january german government purchased doses million per may roche india cipla announced medicine would available india rs per september world health organization urged producers governments address drugs high cost called technology sharing enable manufacture biosimilar versions also said unitaid negotiating roche lower prices equitable distribution especially low middle income november committee medicinal products human use chmp european medicines agency ema recommended granting marketing authorization european union casirivimabimdevimab ronapreve treatment prevention company applied authorization ronapreve roche registration casirivimabimdevimab approved medical use european union november november us food drug administration fda issued emergency use authorization eua casirivimab imdevimab administered together treatment mild moderate people twelve years age older weighing least kilograms lb positive results direct viral testing high risk progressing severe includes years age older certain chronic medical casirivimab imdevimab must administered together intravenous iv infusion subcutaneous casirivimab imdevimab authorized people hospitalized due require oxygen therapy due benefit casirivimab imdevimab treatment shown people hospitalized due monoclonal antibodies casirivimab imdevimab may associated worse clinical outcomes administered hospitalized people requiring high flow oxygen mechanical june eua revised authorize use unapproved product casirivimab imdevimab coformulated product casirivimab imdevimab supplied individual vials administered together treatment mild moderate people aged twelve years age older weighing least kilograms lb positive results direct viral testing high risk progression severe including hospitalization eua issued regeneron pharmaceuticals february committee medicinal products human use chmp european medicines agency ema started rolling review data antibody combination casirivimabimdevimab codeveloped regeneron pharmaceuticals inc f hoffmanla roche ltd roche treatment prevention february chmp concluded combination also known used treatment confirmed people require supplemental oxygen high risk progressing severe central drugs standards control organisation cdsco india may granted emergency use authorization roche use casirivimabimdevimab cocktail country announcement came light second wave pandemic india roche india maintains partnership cipla thereby permitting latter market drug july us fda revised emergency use authorization eua casirivimab imdevimab administered together authorizing emergency use postexposure prophylaxis prevention people aged twelve years age older weighing least kilograms lb high risk progression severe including hospitalization remains authorized treatment mildtomoderate people aged twelve years age older weighing least kilograms lb positive results direct viral testing high risk progression severe including hospitalization april roche regeneron announced phase iii clinical trial regncov met primary secondary endpoints reducing risk infection noninfected participants reducing timetoresolution symptoms symptomatic participants one week vs three weeks placebo june preliminary results form recovery trial showed reduced mortality people produced antibodies total clinical trial people casirivimab imdevimab administered together shown reduce hospitalization emergency room visits people high risk disease progression within days treatment compared safety effectiveness investigational therapy use treatment continues data supporting emergency use authorization eua casirivimab imdevimab based randomized doubleblind placebocontrolled clinical trial nonhospitalized adults mild moderate participants received single intravenous infusion milligrams casirivimab imdevimab mg received mg casirivimab imdevimab mg received placebo within three days obtaining positive viral prespecified primary endpoint trial timeweighted average change viral load viral load reduction participants treated casirivimab imdevimab larger participants treated placebo day however important evidence casirivimab imdevimab administered together may effective came predefined secondary endpoint medically attended visits related particularly hospitalizations emergency room visits within days participants high risk disease progression hospitalizations emergency room visits occurred casirivimab imdevimabtreated participants average compared placebotreated effects viral load reduction hospitalizations er visits similar participants receiving either two casirivimab imdevimab september evaluated part recovery june first results research announced evidence proving effectiveness httpsenwikipediaorgwikicasirivimabimdevimab